Manipulation of dipeptidylpeptidase 10 in mouse and human in vivo and in vitro models indicates a protective role in asthma

Youming Zhang1,6,**, Thanushiyam Poobalasingam2,*, Laura L. Yates2, Simone A. Walker2, Martin S. Taylor3,4, Lauren Chessum4, Jackie Harrison4, Loukia Tsaprouni5,§, Ian M. Adcock5, Clare M. Lloyd2, William O. Cookson1, Miriam F. Moffatt1 and Charlotte H. Dean2,4,¶,**

ABSTRACT
We previously identified dipeptidylpeptidase 10 (DPP10) on chromosome 2 as a human asthma susceptibility gene, through positional cloning. Initial association results were confirmed in many subsequent association studies but the functional role of DPP10 in asthma remains unclear. Using the MRC Harwell Institute N-ethyl-N-nitrosourea (ENU) DNA archive, we identified a point mutation in Dpp10 that caused an amino acid change from valine to aspartic acid in the β-propeller region of the protein. Mice carrying this point mutation were recovered and a congenic line was established (Dpp10145D/145D). Macroscopic examination and lung histology revealed no significant differences between wild-type and Dpp10145D/145D mice. However, after house dust mite (HDM) treatment, Dpp10 mutant mice showed significantly increased airway resistance in response to 100 mg/ml methacholine. Total serum IgE levels and bronchoalveolar lavage (BAL) eosinophil counts were significantly higher in homozygotes than in control mice after HDM treatment. DPP10 protein is present in airway epithelial cells and altered expression is observed in both tissue from asthmatic patients and in mice following HDM challenge. Moreover, knockdown of DPP10 in human airway epithelial cells results in altered cytokine responses. These results show that a Dpp10 point mutation leads to increased airway responsiveness following allergen challenge and provide biological evidence to support previous findings from human genetic studies.

This article has an associated First Person interview with the first author of the paper.

KEYWORDS: DPP10, Point mutation, IgE, Airway resistance, Asthma

INTRODUCTION
Asthma is characterized by intermittent inflammation of the large airways in the lungs with symptoms of wheeze and shortness of breath. The disease is caused by a combination of genetic and environmental factors. Previously, we have established that polymorphisms in DPP10 on human chromosome 2 were associated with asthma traits through positional cloning (Allen et al., 2003). These associations have since been replicated in different ethnic populations worldwide (Wu et al., 2010; Blakey et al., 2009; Zhou et al., 2009; Gao et al., 2010; Mathias et al., 2010). To date, DPP10 is the only gene found to show asthma association by both positional cloning and genome-wide association studies (GWAS) (Mathias et al., 2010). DPP10 encodes a single-pass type II membrane protein that is a member of the S9B family in clan SC of the serine proteases. It has no detectable protease activity in mammals, owing to the absence of a conserved serine residue normally present in the catalytic domain of these proteases (Qi et al., 2003). Instead, DPP10 has been shown to bind specific voltage-gated potassium channels, altering their expression and biophysical properties (Jerrg et al., 2004). Although DPP10 has been associated with asthma in both genome-wide and wet-laboratory studies (Allen et al., 2003; Schade et al., 2008; Kim et al., 2015), its functional role in asthma is almost completely unknown, due in large part to the absence of any genetic models.

Mouse mutants are powerful experimental tools for the study of complex diseases, such as asthma. They have been of great benefit for mapping quantitative traits (Zhang et al., 1999; De Sanctis et al., 1995), and serve as experimental tools to dissect the functional roles of genes in vivo (Zhang et al., 2014). Dpp10145D mice were generated using N-ethyl-N-nitrosourea (ENU)-induced mutagenesis of the mouse genome, which is a conventional method employed for functional analysis (Yates et al., 2009).

To investigate the function of DPP10 in vivo, we obtained full-length mouse Dpp10 complementary DNA (cDNA). We then sequenced four of the 26 exons of Dpp10 in 3840 mouse DNA samples from the UK MRC Harwell archive of ENU-mutagenized F1 DNA samples. The four exons chosen for sequencing include the regions encoding the transmembrane and β-propeller domains of Dpp10, both of which are thought to be required for proper protein function (Allen et al., 2003). Here, we report the establishment of a novel mouse mutant carrying a DPP10 point mutation and its effects on experimental asthma.

RESULTS
Mouse Dpp10 genomic structure
We identified the full-length mouse cDNA of Dpp10 and aligned this with available information on Dpp10. Mouse genomic Dpp10 is located on chromosome 1 and has 26 exons encoding 796 amino acids. The key domains found within the sequence are a transmembrane domain and a β-propeller region (Fig. S1). We therefore screened the ENU DNA archive for mutations within exons encoding either of these domains.
Identifying and validating ENU mutations in Dpp10

From this initial screening, we identified three mutations in 3480 DNA samples. The only nonsynonymous mutation found caused an amino acid change from valine to aspartic acid in exon 5 (Fig. 1A, B). The valine, or at least a hydrophobic residue at this position, is well conserved in DPP10 and DPP6 orthologous sequences throughout vertebrates (Fig. 1C). The wider family of DPPIV domain-containing proteins do not generally conserve this position, but aspartic acid (D) has not been found in any of the proteins defined by the Protein FAMILies database of alignments and Hidden Markov Models (PFAM) profile (Sonnhammer et al., 1998). The mutated residue is on the surface of the protein at the entrance to a pocket in the centre of the β-propeller region. A surface-exposed hydrophobic residue in such a position could well be involved in determining substrate specificity and therefore a mutation in this position is highly likely to have some functional impact on DPP10.

Fig. 1. The Dpp10 mutation and genotyping in mice. (A) Wild-type sequence for Dpp10. (B) Mutant sequence of Dpp10. (C) Alignment of the sequences containing the first β-propeller domain of DPP10 in seven species. (D) Gel comparing the genotyping results from wild-type (left lane) and heterozygous (right lane) Dpp145D littermates. Using forward 5'-AGTCTTGTCTTTACCACA-3' and reverse 5'-AAGCCTCCAGACACTCAC-3' primers, PCR generated a 194 bp product. Restriction enzyme digest with HpyCH4IV cut the wild-type allele at ACGT, producing two bands of 127 bp and 67 bp, whilst the mutant allele remained uncut (194 bp). WT, wild-type mouse, M, mutant mouse.
_recovery and maintenance of Dpp10 mutant mice_ To determine whether the mutation identified would have an impact on DPP10 function _in vivo_, we established a mouse line carrying this mutation, using the corresponding F1 male sperm sample from the Harwell DNA archive (Yates et al., 2009). _In vitro_ fertilization (IVF) with the mutagenized sperm was performed using C3H embryos to facilitate genotyping of the mutation that had been induced in Balb/C mice. We established a genotyping strategy using an enzymatic diagnostic digest with HpyCH4IV, followed by PCR, to distinguish mutant mice from wild-type littermates (Fig. 1D). Seven offspring were obtained, six of which contained the mutant allele, indicating that a single copy of the mutation did not affect mouse viability or fertility. We subsequently established a congenic _Dpp10_ line by backcrossing these mice to CH3 for 10 generations, thereby ensuring that the line did not contain any additional ENU mutations. _Dpp10_ heterozygotes were intercrossed and the genotypes of their offspring were analysed at E18.5. Normal Mendelian ratios of homozygous, heterozygous and wild-type embryos were found, indicating no prenatal mortality and this was confirmed by Chi-squared analysis. Postnatally, _Dpp10_145D homozygotes and heterozygotes were also recovered in expected numbers and these were morphologically indistinguishable from wild-type littermates. All subsequent experiments were conducted using either homozygous _Dpp10_ mice or their wild-type littermates.

_histological examination of Dpp10 mutant mouse lungs_ _Dpp10_145D homozygotes survived to term and histological analysis did not reveal any visible differences in adult lung architecture (Fig. S2). We investigated the localization of _Dpp10_ protein in both wild-type and homozygous _Dpp10_ mutant lungs by immunostaining. In phosphate-buffered saline (PBS)-treated wild-type and _Dpp10_145DS/145D_ lungs, we observed a subset of airway epithelial cells with _Dpp10_-positive staining (Fig. 2A,B). _Dpp10_ staining was much more visible in the airways of both wild-type and mutant mice treated with HDM than in PBS-treated mice (Fig. 2C,D). Staining of sections from the same samples shown in Fig. 2C and D with club cell-10 (CC10), a club cell marker, highlights differences in the patterns of _Dpp10_ and CC10 staining (Fig. 2E,F). The discrepancy is particularly striking in _Dpp10_ homozygous airways (Fig. 2D versus F). More detailed comparison of _Dpp10_ localization in wild-type and _Dpp10_145D_ airway cells showed that in wild-type airways, staining was frequently observed at the apical surface of cells, whereas in mutant airways, cells with apical _Dpp10_ staining were much rarer (P<0.05, Fig. 2F,H). A control section where the primary antibody was omitted shows no DAB staining (Fig. 2G). These data indicate that the point mutation in _Dpp10_145D leads to altered protein localization rather than complete loss of protein. Further analysis of the lungs showed no visible differences in the cell-type specific markers pro-surfactant protein-C, CC10, smooth muscle actin (SMA) or aquaporin-5 between _Dpp10_ homozygotes and wild-type mice (Fig. S3), indicating that the _Dpp10_ mutation does not affect cell differentiation.

_the response of Dpp10 mutant mice to house dust mite challenge_ To determine whether the _Dpp10_145D mutation had a functional impact and, in particular, whether the mutation might modify airway hyper-responsiveness (AHR), we dosed wild-type (n=9) and _Dpp10_ homozygous (n=10) mice with 25 µg house dust mite extract (HDM) three times per week for 3 weeks using a previously established protocol (Gregory et al., 2009). Mice were then challenged using a methacholine dose response curve 24 h after the final HDM dose. Airway responsiveness was initially assessed in a whole-body plethysmograph, using Penh. At baseline and at lower doses of methacholine (12.5 mg/ml and 25 mg/ml), we found no significant difference in Penh between wild-type and _Dpp10_ homozygotes (Fig. S4A); however, at the highest dose of methacholine tested (50 mg/ml), _Dpp10_ homozygotes showed a significant increase in Penh (Fig. S4B) (P<0.05).

Following plethysmograph experiments, which indicated increased airway resistance in _Dpp10_ homozygous mice, we conducted a further HDM challenge prior to directly testing respiratory function using the forced oscillation technique (FlexiVent). _Dpp10_ HDM-treated mutant mice showed significantly increased airway resistance in response to methacholine challenge (Fig. 3A) at 100 mg/ml compared to wild-type HDM-treated mice (P<0.05, Fig. 3B). _Dpp10_ HDM-treated mutant mice also showed significantly increased elastance (Fig. 3C,D, P<0.05) and decreased compliance (Fig. 3E,F, P<0.05) in response to methacholine challenge at 100 mg/ml compared to wild-type HDM-treated mice.

To analyse the response of _Dpp10_ homozygous mice to allergen challenge further, we assessed a number of hallmarks of allergic airways disease. IgE levels in serum of HDM-treated _Dpp10_145D_ mice were significantly higher compared to those in wild-type HDM-treated littermates (Fig. 4A, P<0.05). We also found an increased percentage of eosinophils in bronchoalveolar lavage fluid (BALF) of _Dpp10_145DS/145D_ HDM-treated mice compared to that in the wild-type HDM group (Fig. 4B, P<0.05). Quantification of collagen thickness around airways showed a trend towards increased thickness in _Dpp10_145D_ homozygotes; however, this was not statistically significant (Fig. 4C,D). We did not observe any noticeable difference in goblet cell numbers across all groups of mice (Fig. 4E,F).

DPP10 protein is present in human asthmatic airway epithelial cells and modulation of DPP10 affects key inflammatory mediators In order to investigate the possible functional roles of DPP10 in human lungs, we also investigated DPP10 expression in asthma patients. In agreement with our findings in mouse, we found very little DPP10 protein in the bronchial airway epithelium of healthy subjects. By contrast, expression was enhanced in the epithelium of asthmatic patients (Fig. 5A). As with the murine data, DPP10 was only seen in some epithelial cells.

Data from the murine model indicated a potential protective role of DPP10 in the airways so we investigated the effects of DPP10 knockdown and overexpression in human bronchial epithelial cells (BEAS-2B). _Dpp10_ small interfering RNA (siRNA) effectively silenced the expression of DPP10 (Fig. 5B). Knockdown of DPP10 enhanced IL1β-induced leukocyte proteinase inhibitor (SLPI) release from BEAS-2B cells, although this did not reach significance (Fig. 5C). By contrast, overexpression of DPP10 resulted in a significant reduction in IL1β-induced SLPI release (Fig. 5C). As the functional effect of _Dpp10_ in vivo suggested a possible effect on endogenous anti-inflammatory corticosteroid production, we examined the effect of _Dpp10_ modulation on the glucocorticoid receptor (GR). _Dpp10_ knockdown attenuated the ability of GR to translocate to the nucleus and bind to DNA, whereas DPP10 overexpression significantly enhanced GR activation even without dexamethasone treatment (Fig. 5D). These data were confirmed by western blot analysis of GR nuclear translocation in BEAS-2B cells (Fig. 5D, lower panels).

To further investigate whether DPP10 could modulate cytokine release, we also conducted siRNA-mediated knockdown of DPP10 in primary epithelial cells (normal human bronchial epithelial
Fig. 2. See next page for legend.
Knockdown with 150 nM DPP10 siRNA for 48 h resulted in a 66% reduction in DPP10 transcript levels, compared to the control. Following siRNA knockdown, NHBE cells were stimulated with IL1β and the levels of IL8 (Fig. 5E) and IL6 (Fig. 5F) released from control and DPP10 knockdown cells were measured at 0, 4, 10, 16, 24 and 30 h following stimulation. DPP10 knockdown increased the level of IL8 and IL6 released from NHBE cells at 24 and 30 h (the increase was statistically significant for IL8 but not IL6). These results are consistent with the idea that Dpp10 plays a protective role in asthma.

DISCUSSION

Using a Dpp10 point mutant, with a valine to aspartic acid change in the β-propeller region, we demonstrated that homozygous mutant mice exhibit greater AHR following HDM challenge than wild-type animals. We also find that DPP10 protein is present in airway epithelial cells and Dpp10 immunostaining is increased in mice following HDM challenge; this corresponds with clinical findings where asthmatic patients show increased DPP10 in lungs compared to controls. Modulation of DPP10 in BEAS-2B and NHBE cells resulted in altered levels of cytokine release following IL1β stimulation, as well as modified glucocorticoid function. These results provide biological evidence to support previous findings from human genetic studies indicating that DPP10 is an asthma susceptibility gene.

Positional cloning and GWAS have identified several genes that are associated with asthma. Understanding the functions of these genes is an important next step to shed light on the aetiology of asthma.
particularly important for genes like *Dpp10*, where very little is known about their biological function in the lungs (Zhang et al., 2012). The association of *DPP10* with asthma has been confirmed across several different ethnic populations (Wu et al., 2010; Blakey et al., 2009; Zhou et al., 2009; Gao et al., 2010; Mathias et al., 2010). In addition, recent studies have shown that *DPP10* genetic variants affect lung function decline in ageing (Poon et al., 2014), and have also been associated with aspirin-exacerbated respiratory disease (Kim et al., 2015). *DPP10* is a potassium channel-associated protein (Chen et al., 2014; Kitazawa et al., 2015), but unlike other DPP family members, mammalian *DPP10* lacks enzymatic activity and is unable to cleave terminal dipeptides from asthma-related cytokines and chemokines (Allen et al., 2003). Interestingly, however, in *Drosophila*, *DPP10* both acts as an ion channel substrate and has peptidase activity (Shina et al., 2016).

DPP proteins contain a β-propeller domain, which regulates substrate access to an α/β-hydrolase catalytic domain. Most interactions of *DPP10* with other proteins are likely to occur on the β-propeller domain so it is significant that the mutation in *Dpp10* is in this domain (Chen et al., 2014). In the brain, *DPP10* malfunction is associated with neurodegenerative conditions such as Alzheimer’s disease and frontotemporal lobe dementia. Moreover, *DPP10* variants in neurons have been shown to alter potassium channel-gating kinetics (Jerng et al., 2007), and additional studies have shown that *DPP10* modulates the electrophysiological properties, cell-surface expression and subcellular localization of voltage-gated potassium channels (Bezerra et al., 2015). Given the location of the mutation in the *Dpp10* mouse line, it is tempting to speculate that ion channel-gating kinetics could also be altered in the lungs of these mice.

Like human *DPP10*, mouse *Dpp10* has 26 exons and multiple splice variants, which retain the transmembrane domain and β-propeller domains. Mouse ENU mutagenesis has proven to be a powerful tool for studies of human diseases, particularly prior to the discovery of Crispr/Cas9 gene editing techniques. Through backcrossing, mice harbouring the selected mutation on a congenic background can be obtained (Keays et al., 2006). In the current experiment, we identified one nonsynonymous mutation, resulting in an amino acid change from valine to aspartic acid in the β-propeller domain of *Dpp10*. Careful comparison of embryonic *Dpp10* homozygotes and wild-type littermates did not reveal any visible phenotype, indicating that the *Dpp10* mutation does not affect the development of mouse lungs.

Fig. 4. *Dpp10* homozygous mice develop allergic inflammation in the lungs after HDM challenge. (A,B) Exposure of *Dpp10* homozygotes to HDM resulted in enhanced serum IgE levels (A) and elevated eosinophil counts in bronchoalveolar lavage fluid (BALF) (B) compared to wild-type littermates. (C-F) *Dpp10* homozygotes showed a nonsignificant trend towards increased peribronchiolar collagen (C,D) and goblet cell numbers compared to wild-type littermates (E,F). Data are means±s.e.m.; n=4 mice for all groups of IgE (A); n=4 for WT PBS, WT HDM and *Dpp10* PBS groups, n=6 for *Dpp10* HDM group (B); n=4 for WT PBS, *Dpp10* PBS and *Dpp10* HDM groups, n=6 for WT HDM group (C); n=3 for WT and *Dpp10* HDM groups (E). Mann–Whitney U-test, *P<0.05, ***P<0.001. Scale bars: 12.5 µm in D, 25 µm in F.
In this study, we found that mouse Dpp10 is localized to the airway epithelium, and more Dpp10 is visible in airways, after HDM treatment. This finding is consistent with a previous report showing Dpp10 protein in the airway epithelium of rat lungs (Schade et al., 2008). Comparison of airways stained for Dpp10 and CC10, a marker of club cells, indicates that not all club cells are positive for Dpp10 protein in human asthmatic airways and modulates release of inflammatory mediators from human airway epithelial cells. (A) Representative immunohistochemical staining of bronchial biopsies from asthmatic and normal healthy subjects. Results are representative of samples from three subjects. (B) A concentration-dependent reduction in DPP10 protein expression was observed after 24 h in BEAS-2B cells following siRNA knockdown. (C) DPP10 overexpression suppresses IL1β-induced SLPI release from BEAS-2B cells, whereas DPP10 knockdown results in an increase in SLPI release. (D) DPP10 knockdown also attenuates the ability of the glucocorticoid receptor (GR) to be activated by dexamethasone, whereas DPP10 overexpression enhanced GR DNA binding. The lower panel shows representative western blots of GR translation. (E) IL8 levels in supernatants from DPP10 knockdown NHBE cells and control cells after 0-30 h stimulation of IL1β. (F) IL6 levels in supernatants from DPP10 knockdown and control NHBE cells after 0-30 h stimulation of IL1β. Data are mean±s.e.m. from three or four independent experiments. Student’s t-test, ***P<0.001 versus control; ###P<0.001, ##P<0.01 and #P<0.05 versus stimulated samples; ns, nonsignificant.

Fig. 5. DPP10 is increased in human asthmatic airways and modulates release of inflammatory mediators from human airway epithelial cells. (A) Representative immunohistochemical staining of bronchial biopsies from asthmatic and normal healthy subjects. Results are representative of samples from three subjects. (B) A concentration-dependent reduction in DPP10 protein expression was observed after 24 h in BEAS-2B cells following siRNA knockdown. (C) DPP10 overexpression suppresses IL1β-induced SLPI release from BEAS-2B cells, whereas DPP10 knockdown results in an increase in SLPI release. (D) DPP10 knockdown also attenuates the ability of the glucocorticoid receptor (GR) to be activated by dexamethasone, whereas DPP10 overexpression enhanced GR DNA binding. The lower panel shows representative western blots of GR translation. (E) IL8 levels in supernatants from DPP10 knockdown NHBE cells and control cells after 0-30 h stimulation of IL1β. (F) IL6 levels in supernatants from DPP10 knockdown and control NHBE cells after 0-30 h stimulation of IL1β. Data are mean±s.e.m. from three or four independent experiments. Student’s t-test, ***P<0.001 versus control; ###P<0.001, ##P<0.01 and #P<0.05 versus stimulated samples; ns, nonsignificant.
Dpp10, because CC10-stained cells are more prevalent than Dpp10-positive cells. Our data indicate that at least some CC10-positive cells are also positive for Dpp10. However, further investigation with additional cell type-specific markers will be required to determine which subtype(s) of airway epithelial cells express Dpp10, e.g. basal cells, ciliated cells etc. Comparison of the subcellular pattern of CC10 staining with that of DPP10 revealed differences in the localization of these two proteins. Moreover, the localization of Dpp10 protein is different in airways of wild-type and Dpp10 knockout mice, there are significantly fewer cells with Dpp10 at the apical surface in mutant lungs. These observations indicate that loss of function in the Dpp10 mouse is likely to result from altered protein function rather than lack of protein. This is a frequent consequence of point mutations in both mouse models and in the human population (Poobalasingam et al., 2017; Piel et al., 2017).

HDM is one of the commonest aeroallergens worldwide and up to 85% of asthmatics are typically HDM allergic. Inhalation of HDM by naïve mice results in lung function changes, including increased resistance and reduced compliance, as well as recruitment of inflammatory leukocytes (Gregory et al., 2009; Johnson et al., 2004). HDM challenge initiates a Th2-polarized response with T2 helper cytokines being produced in both BALF and lungs of mice, including IL4, IL5 and IL13, and typically an influx of eosinophils and increase in IgE levels. This cytokine response is important, driving the development of airway remodelling, which occurs after the Th2 cytokine response, and altered lung function (Gregory et al., 2009; Johnson et al., 2007).

Our results show that after HDM challenge, Dpp10 homozygotes display significantly increased AHR upon methacholine challenge compared to wild-type littermates. Specifically, resistance and elastance are increased and compliance is reduced. Following HDM treatment, serum IgE levels and eosinophil counts in BALF were significantly higher in Dpp10 mutants after HDM treatment. Although collagen thickness and goblet cell numbers were not significantly increased, it is known that these hallmarks of airway remodelling only become significantly altered after a longer and more frequent HDM dosing regimen than the one used here (Gregory et al., 2009, 2010; Johnson et al., 2004).

In asthmatics, exposure to the allergen HDM triggers the release of cytokines as a result of mite-derived protease activity (Seto et al., 2009). Anti-proteases such as SLPI can inhibit this cytokine release. SLPI is an anti-inflammatory gene induced by glucocorticoid in human epithelial cells and low SLPI has been associated with severe asthma in mice and humans (Sallenave et al., 1994; Raundhal et al., 2015). In this study, we showed that DPP10 overexpression in BEAS-2B cells results in lower levels of SLPI release following cytokine stimulation and enhanced corticosteroid activity. In combination with our finding that DPP10 knockout in primary human bronchial epithelial cells leads to increased IL8 and IL6 release, these data demonstrate that alterations in DPP10 levels can modify the inflammatory response in lung epithelial cells.

In summary, we have established a congenic mouse line harbouring a mutation in the β-propeller domain of DPP10. Our data provide functional experimental evidence supporting previous human genetic data indicating that DPP10 is an asthma susceptibility gene. Results from both murine and human in vivo and in vitro analyses suggest that DPP10 might play a protective role in asthma. The novel Dpp10 mouse mutant reported here provides a means to investigate the functional roles of Dpp10 in vivo, for the first time. Understanding how the mutant Dpp10 potassium voltage-gated ion channel complex is impacted by the DPP10I45D mutation, and how this affects other inflammatory associated factors such as TGFβ and IL33, will be important future studies.

**MATERIALS AND METHODS**

**Full-length cDNA of Dpp10 and exon sequencing**

A mouse cDNA clone (BE162767) was obtained and extended via its 5’ and 3’ ends to a full-length cDNA using rapid amplification of cDNA ends (RACE) (Clontech). The primary transcript encodes a novel 2370 bp open reading frame (ORF) with a predicted peptide sequence of 789 residues. To identify mutations in Dpp10, we screened four exons of Dpp10 (2, 5, 6 and 7) in 3840 mutagenized BALB/C DNA samples from the UK MRC Harwell University archive by sequencing the PCR products. Exon 2 encodes the transmembrane amino acids and exon 5, 6, and 7 encode the first and second β-propellers of the peptide. PCR primer sequences are listed in Table S1. PCR conditions were as follows: 35 cycles consisting of (i) 60 s at 94°C, followed by (ii) 60 s at 50-60°C and then (iii) 30 s at 72°C. PCR products from all 3840 DNA samples were purified with Millipore purification plates and sequenced using an ABI 3700 sequence machine. Sequence traits were aligned and DNA samples carrying mutations were identified. The mutation predicted to most likely affect function was used to establish the DPP10 mouse line.

**Mouse line recovery and maintenance**

Mice were housed and maintained in accordance with the rules and regulations of the UK Animals (Scientific Procedures) Act 1986, and the Harwell Animal Welfare and Ethical Review Body (AWERB). Mice were maintained in specific pathogen-free conditions and provided food and water ad libitum. Sperm containing the Dpp10 mutation identified above was recovered from the parallel Harwell sperm archive and used in IVF with C3H females to obtain live mice carrying this Dpp10 mutation. Progeny born following IVF were genotyped using a diagnostic restriction enzyme digest followed by PCR as follows: (i) 60 s at 94°C, (ii) 60 s at 55°C and (iii) 30 s at 72°C for 32 cycles. PCR products were digested with the HpyC41IV′ enzyme (2 U for 3 h), then run on a 2% agarose gel to determine the size of products. The mutant Dpp10 band was 194 bp and wild-type DNA was cut into two fragments of 127 bp and 62 bp. We subsequently established a congenic Dpp10 line by backcrossing these mice to C57/10 for 10 generations.

**Histology and immunostaining of lung tissues**

Adult human lung tissue was obtained from the Biobank of the Respiratory Biomedical Research Unit (BRU), Royal Brompton and Harefield NHS Foundation Trust. The study was approved by the Trust’s Ethics Committee (ethics reference number 10/H0504/9). Informed written consent was obtained from all study subjects. Control samples were obtained from healthy, nonasthmatic volunteers. Four micrometre paraffin sections or 10 µm cryosections were stained with Haematoxylin and Eosin (H&E), Mauritus Scarlet Blue (MSB) to identify collagen, or immunostained using previously established protocols (Yates et al., 2010). Lung tissue processing and immunohistochemistry were performed as previously described (Varani et al., 2006). Antibodies used were as follows: anti-aquaporin-5, 1:400, Santa Cruz Biotechnology; anti-CC-10, 1:500, Santa Cruz Biotechnology; anti-pro-SP-C, 1:1000, Chemicon; anti-alpha SMA, 1:1000, Lab Vision. Incubations were overnight at 4°C. For CC10 immunostaining, antigen retrieval using citrate buffer (pH 6) was required to unmask antigens prior to immunodetection. Antibodies were detected with either a universal (alpha SMA, pro-SP-C) or goat (CC10, aquaporin-5) ABC elite staining kit (Vector Labs). Rabbit anti-DPP10 was obtained from Santa Cruz Biotechnology (sc-174156) or Aviva Systems Biology (OAAB05596) and used at 1:100 dilution. Controls, where the primary antibody was omitted, were included in each immunostaining experiment.

**Quantifying the percentage of airway cells with apical Dpp10 immunostaining**

The total number of cells in individual airways was determined by counting the number of Haematoxylin-stained nuclei. The percentage of cells with apical Dpp10 staining in each airway was determined by expressing the...
number of cells with brown staining visible at the apical surface of cells (i.e. immediately adjacent to the lumen) as a percentage of total airway cells. Eight airways from n=3 mice per group were analysed.

**Allergen sensitization**

Eight- to 10-week-old mice (no more than 1 week difference in age within any one experiment) were dosed with purified HDM extract (batch number 7500, Greer Laboratories, NC, USA; 21.26 µg derP/mg protein, 13.55 endotoxin U/mg) intranasally (1 µg/µl in 25 µl PBS three times/week for 3 weeks; littermate control mice received PBS only). Lung function testing was carried out 24 h after the last dose.

**Measurements of AHR**

Unrestrained conscious mice (male and female) were placed into a plethysmograph chamber (Buxco Europe, Hampshire, UK). Airway resistance was measured as Penh (enhanced pause) (Solberg et al., 2006). Baseline Penh was measured for 5 min, after which time an aerosol of methacholine (Sigma-Aldrich, Dorset, UK) was given and Penh was again measured for 5 min. The change in Penh was calculated between baseline and each subsequent methacholine dose.

Respiratory mechanics were also directly measured using the forced oscillation technique (FlexiVent system, SCIREQ) in anaesthetized, ventilated female mice 24 h postchallenge. Following lung function measurements, serum, BALF and lung tissue samples were collected and processed based on methods by Hamelmann et al. (1997). BALF was collected using 3×0.4 ml sterile PBS and centrifuged. The supernatant was stored for further analysis, and the cell pellet was re-suspended in 0.5 ml RPMI, supplemented with 10% foetal bovine serum, penicillin and streptomycin. Then, 50,000 cells were spun at 31 g for 4 min using a Cytospin3 (Shandon) and fixed in methanol for 5 min. Cells were stained using Wright-Giemsa stain (Sigma-Aldrich) following the manufacturer’s instructions. Eosinophil percentages were obtained by determining the integrated density of staining around each airway was determined. Image analysis was performed using Fiji software. For each mouse, four airways were measured and the mean average was calculated.

Goblet cells counts were obtained using the protocol described in Townsend et al. (2000). Periodic Acid-Schiff (PAS)-stained goblet cells in airway epithelium were counted in 4 µm wax lung sections. Counting was undertaken blind using a numerical scoring system (0, 5% goblet cells; 1, 5 to 25%; 2, 25 to 50%; 3, 50 to 75%; 4, >75%). The sum of airway scores from each lung was divided by the number of airways examined (20-50 per mouse) and expressed as mucus cell score in arbitrary units (U).

**Cell culture of human bronchial airway epithelial cells**

Bronchial epithelial transformed cells (BEAS-2B) were purchased from LGC standards (Teddington, UK). No contamination was found in the cell stock. The cells were cultured in keratinocyte media, supplemented with recombinant human epithelial growth factor (rhEGF) and bovine pituitary extract (BPE) (all Gibco, Paisley, UK) as previously described (Khan et al., 2014). Following overnight culture in minimal media to enable synchronization, cells were stimulated with IL1β (10 ng/ml, Sigma-Aldrich) or dexamethasone (Sigma-Aldrich) and proteins isolated at 2 h or 24 h for analysis of supernatants by enzyme-linked immunosorbent assay (ELISA). Proteins were extracted from cells using a nuclear extraction kit (Active Motif, Rixensart, Belgium) following the manufacturer’s instructions.

**Knockdown and overexpression of DPP10 in BEAS-2B cells**

DPP10 gene expression was knocked down using 50 nM ON-TARGETplus SMART pool siRNA (Thermo-Scientific Dharmacon, CO, USA) against the DPP10 gene as described previously (Khan et al., 2014). Silencer select siRNA (Ambion, TX, USA) was used as a control for transfection. The DPP10 clone 11 (Allen et al., 2003) was overexpressed using jetPEI (Polyplus-transfection, Illkirch, France) according to the manufacturer’s instructions.

**Knockdown of DPP10 in NHBE cells**

Primary NHBE cells were obtained from Lonza and no contamination was found in the cell stock. The cells were cultured to a maximum of five passages to limit variable responses in bronchial epithelial medium (hAEC Culture Medium, Epithelix). Cells were seeded into 24-well plates (Corning Costar Corp.) at 4×10^5 cells/well to reach 40-60% confluence on the day of transfection. RNA interference (RNAi) was carried out using 150 nM ON-TARGETplus SMARTpool (Dharmacon Research Inc., Lafayette, CO, USA) or ON-TARGETplus Non-targeting Pool negative control. RNAi complexes were added to the cells, which were placed in a CO2 incubator at 37°C for 48 h. Following transfection, the culture medium was changed and then stimulated with 1 ng/ml IL1β. Cell supernatants were collected at different time points poststimulation (0, 4, 10, 16, 24 and 30 h) for cytokine measurement. Quantitative PCR primer sequences were as follows: DPP10 forward primer 5′-GTGAAAGGTCAAAGGTC-3′; reverse primer 5′-CT GGCCTTTCTATCTTCTTC-3′. GAPDH forward primer 5′-TCAAG AAGGTGTTGGAACAGC-3′; reverse primer 5′-CCGTGTGTAAG TCAGAGGAG-3′.

**ELISA**

Levels of secretory leukocyte protease inhibitor (SLPI) in the supernatant were measured by ELISA, following the manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA), 24 h after cell stimulation. Human IL6 and IL8 were measured with an ELISA DuoSet (R&D Systems Europe, Abingdon, UK), according to the manufacturer’s instructions. Mouse serum IgE levels were measured by ELISA using purified anti-mouse IgE capture antibody (553413, BD Pharmingen), according to the manufacturer’s instructions.

**Western blotting**

Western blotting was performed as described previously (Khan et al., 2014) using an anti-GR antibody (H-300, Santa Cruz Biotechnology) at 1:1000 dilution, and visualized using Luminata™ Forte solution (Millipore, Billarica, MA, USA) with exposure to X-ray film (Fisher Scientific, Loughborough, UK).

**Statistical analysis**

Graphs were generated using GraphPad Prism software (GraphPad version 5.0, La Jolla, CA, USA) or Microsoft Excel. Where appropriate, sample sizes were determined using power calculations based on previous experimental data. Data are expressed as mean±s.e.m. Data on resistance, elastance and compliance at 100 mg/ml methacholine and ΔPenh at 50 mg/ ml methacholine are expressed as box and whisker plots showing the median, interquartile range, and minimum and maximum values. For HDM challenge experiments, statistical significance of HDM-treated versus PBS control groups in wild-type and Dpp10^−/− mice was determined by a two-tailed P value using the Mann–Whitney U-test when comparing two groups only. For knockdown experiments in human cells, graphs show mean ±s.e.m. of SLPI, IL6 and IL8 for DPP10 knockdown cells and control cells. Differences between groups were tested using a two-tailed Student’s t-test. P<0.05 was considered significant for all statistical analyses.

**Competing interests**

The authors declare no competing or financial interests.

**Author contributions**


Funding
This work was supported by the Wellcome Trust (WT 077859 and WT096964; Senior Investigator Award to W.O.C. and M.F.M.), the Medical Research Council, the National Heart and Lung Institute (C.H.D.) and Research Councils UK (Research Councils UK Fellowship to Y.Z.). C.H.D. was also supported by core funding from MRC Harwell. I.M.A. was supported by the Innovative Medicines Initiative Joint Undertaking (IMI-JU) programme U-BIOPRED (EU grant number 115010).

Supplementary information
Supplementary information available online at http://dmm.biologists.org/lookup/doi/10.1242/dmm.031369.supplemental

The work was supported by the Wellcome Trust (WT 077859 and WT096964; Senior Investigator Award to W.O.C. and M.F.M.), the Medical Research Council, the National Heart and Lung Institute (C.H.D.) and Research Councils UK (Research Councils UK Fellowship to Y.Z.). C.H.D. was also supported by core funding from MRC Harwell. I.M.A. was supported by the Innovative Medicines Initiative Joint Undertaking (IMI-JU) programme U-BIOPRED (EU grant number 115010).

This work was supported by the Wellcome Trust (WT 077859 and WT096964; Senior Investigator Award to W.O.C. and M.F.M.), the Medical Research Council, the National Heart and Lung Institute (C.H.D.) and Research Councils UK (Research Councils UK Fellowship to Y.Z.). C.H.D. was also supported by core funding from MRC Harwell. I.M.A. was supported by the Innovative Medicines Initiative Joint Undertaking (IMI-JU) programme U-BIOPRED (EU grant number 115010).

References